2020年6月8日在上午8:00 EDT

董事NGM生物拓展委员会与阿玲浩,医学博士的任命

南旧金山,加利福尼亚州,2020年6月8日(GLOBE NEWSWIRE) - NGM生物制药公司(NGM)(纳斯达克股票代码:NGM),一家生物技术公司,专注于发现和培养变革治疗的患者,今天宣布卡罗尔的任命Ho, M.D. to its Board of Directors. Dr. Ho currently serves as Chief Medical Officer and Head of Development at Denali Therapeutics.

“阿玲的背景作为一名医生,科学家与深厚的行业知识非常适合NGM的文化和愿景,我们很高兴能欢迎她加入董事会,”戴维·伍德豪斯,博士,NGM的首席执行官说。“我们将继续前进aldafermin,我们对治疗非酒精性脂肪性肝炎或NASH,对后期开发和商业化主角人选。同时,我们正在取得进展在肿瘤学和临床眼科方案,包括NGM621,我们的地理萎缩抗补体C3抗体的程序。Given Carole’s experience spanning early- to late-stage clinical development, we look forward to her insights as we design and execute our late-stage NASH clinical development program and other clinical programs and translate various exciting, novel early-stage opportunities into viable clinical development candidates.”

何医生说:“NGM塑造出在NASH发展景观aldafermin一个突出的位置。此外,搭载了其深厚的生物制剂和生物研究的发动机,再加上强大的临床开发基础设施,NGM已建成的管道是远远超出NASH。亚博游戏官网网址这需要创造力和周到的策略,特别是对于一个新兴的成长型企业,以临床培养计划取得成果在多个治疗领域。我期待着与大卫的工作,我的同事NGM董事会成员和NGM团队,最大限度地为NGM机会的广度,进而,为患者“。

在2015年以来她作为首席医疗官和发展在迪纳利负责人的角色,何博士已经建立了一个综合开发机构,负责从前期IND指导治疗考生通过对最终的审批实现研究。在加入迪纳利,何博士曾担任早期临床开发副总裁在Genentech公司,在那里她负责所有非肿瘤学适应症,包括CV-代谢,眼科,神经内科,感染交付关键试验准备的治疗候选物疾病,呼吸道,风湿病和肠胃病。八年,她在Genentech,何博士举办各种治疗领域跨越多个早期和后期临床方案的几个高级领导职务。在她的职业生涯早期,何博士在马克·泰西 - 拉维尼博士的实验室担任访问科学家在Genentech,同时也作为一名教师的神经学在斯坦福大学的系。

何博士完成了她的神经内科住院医师哈佛医学院在马萨诸塞州总医院/布里格姆妇女医院,在那里她担任首席驻地。她获得了医学博士,康奈尔大学和她的学士学位从哈佛学院生化科学。除了她的任命NGM的董事会,何博士还担任束治疗的董事会。

关于NGM生物制药公司

NGM是一家生物制药公司,致力于发现和基于有氧代谢,肝,肿瘤学和眼科疾病潜在的关键生物学途径的科学认识,开发创新疗法。我们充分利用我们的生物学中心的药物发现方法的行动揭开新的机制和生成专有的见解,使我们能够迅速进入验证的概念研究,并提供潜在的先入类药物病人。在NGM,我们渴望在经营生物制药行业最有生产力的研究和开发引擎之一,在临床开发多个程序。请访问我们的www.uglyoverload.com想要查询更多的信息。

前瞻性声明

所包含的关于不属于历史事实有关本新闻稿中的“前瞻性陈述”的词语1995年私人证券诉讼改革法案中所指的诸如“期待”,“前进”,“进步”,“位置“,‘最大化’和类似表述(以及其他的词语或表达参照未来的事件,条件或环境)旨在识别前瞻性陈述。这些陈述包括那些涉及:对后期开发等临床前和临床开发进度aldafermin的进步;NGM的机会潜力广度;而不是历史事实的其他声明。Because such statements deal with future events and are based on NGM’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of NGM could differ materially from those described in or implied by the forward-looking statements in this press release. These risks and uncertainties include, without limitation, risks and uncertainties associated with: the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully enrolling or completing clinical studies, the risk that the results obtained to date in NGM’s clinical trials may not be indicative of results obtained in pivotal or other late-stage trials, and the risk that NGM’s ongoing or future clinical studies in humans may show that aldafermin is not a tolerable and effective treatment for NASH patients; the evolving effects of the COVID-19 pandemic on NGM’s business and operations, as well as those of third parties on which NGM relies; the time-consuming and uncertain regulatory approval process; NGM’s reliance on third-party manufacturers for aldafermin and its other product candidates; the sufficiency of NGM’s cash resources and need for additional capital; and other risks and uncertainties affecting NGM and its development programs, including those described under the caption “Risk Factors” in NGM’s quarterly report on Form 10-Q for the quarter ended March 31, 2020 and future filings and reports that NGM makes from time to time with the United States Securities and Exchange Commission. Except as required by law, NGM assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

投资者联系方式:
西尔维亚·惠勒和亚历山德拉·桑托斯
swheeler@wheelhouselsa.com
asantos@wheelhouselsa.com
ir@ngmbio.com
媒体联系:
利兹Melone酒店
media@ngmbio.com


股票报价

联系信息

投资者关系:
ir@ngmbio.com

媒体关系:
media@ngmbio.com

最佳